Compare BTDR & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTDR | WVE |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | Singapore | Singapore |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | 2021 | 2015 |
| Metric | BTDR | WVE |
|---|---|---|
| Price | $8.04 | $15.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 16 |
| Target Price | $25.10 | ★ $30.44 |
| AVG Volume (30 Days) | ★ 7.5M | 2.8M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,704,000.00 |
| Revenue This Year | $89.44 | N/A |
| Revenue Next Year | $68.00 | $15.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $6.84 | $5.28 |
| 52 Week High | $27.80 | $21.73 |
| Indicator | BTDR | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 32.30 | 66.97 |
| Support Level | $7.55 | $15.23 |
| Resistance Level | $14.47 | $18.50 |
| Average True Range (ATR) | 0.88 | 0.69 |
| MACD | -0.30 | 0.26 |
| Stochastic Oscillator | 9.98 | 98.64 |
Bitdeer Technologies Group is principally engaged in provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.